Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporine A enhances platelet aggregation.

A A Grace1, M A Barradas, D P Mikhailidis

  • 1Department of Nephrology and Transplantation, Royal Free Hospital and School of Medicine, London, United Kingdom.

Kidney International
|December 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chloral Hydrate versus Isofluorane anesthesia and their differential impact on the midbrain system.

Journal of neuroscience methods·2026
Same author

The medial septum enhances reversal learning via opposing actions on ventral tegmental area and substantia nigra dopamine neurons.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2019
Same author

Correction: Altered activation and connectivity in a hippocampal-basal ganglia-midbrain circuit during salience processing in subjects at ultra high risk for psychosis.

Translational psychiatry·2018
Same author

Altered activation and connectivity in a hippocampal-basal ganglia-midbrain circuit during salience processing in subjects at ultra high risk for psychosis.

Translational psychiatry·2017
Same author

Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia.

Molecular psychiatry·2017
Same author

Response to: Depolarization vs. repolarization: what is the mechanism of ventricular arrhythmogenesis underlying sodium channel haploinsufficiency in mouse hearts?

Acta physiologica (Oxford, England)·2016
Same journal

Why current evidence does not support routine C5 inhibition in STEC-HUS.

Kidney international·2026
Same journal

Beyond galactose deficiency: redefining pathogenic IgA in IgA nephropathy.

Kidney international·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026
Same journal

Crystal-storing histiocytosis causing severe acute kidney injury.

Kidney international·2026
Same journal

Peritoneal dialysis in a patient with extensive burn scarring.

Kidney international·2026
See all related articles

Cyclosporine A (CyA) therapy increases platelet aggregation and thromboxane A2 release, potentially contributing to thromboembolic events and nephrotoxicity. Platelet function normalized after switching from CyA to azathioprine.

Area of Science:

  • Pharmacology
  • Nephrology
  • Hematology

Background:

  • Cyclosporine A (CyA) is associated with increased thromboembolic episodes.
  • The precise mechanisms underlying CyA-induced thrombotic events require further elucidation.

Purpose of the Study:

  • To investigate the effects of Cyclosporine A (CyA) on platelet aggregation and thromboxane A2 release.
  • To explore the clinical implications of CyA's impact on platelet function in renal allograft recipients.

Main Methods:

  • In vitro studies using platelet-rich plasma from healthy subjects.
  • In vivo studies involving CyA ingestion by healthy volunteers.
  • Analysis of platelet function in renal allograft recipients undergoing CyA therapy.

Main Results:

Related Experiment Videos

  • Cyclosporine A enhanced platelet aggregation in response to various agonists (adrenaline, collagen, ADP) both in vitro and in vivo.
  • Platelets from CyA-treated renal allograft recipients exhibited hyperaggregability and increased thromboxane A2 release, correlating with plasma CyA concentrations.
  • Platelet function normalized upon switching from CyA to azathioprine, and remained normal in patients on nifedipine despite CyA therapy.

Conclusions:

  • Cyclosporine A-mediated platelet activation may contribute to thromboembolic phenomena associated with its use.
  • Increased thromboxane A2 release, a vasoconstrictor, may play a role in Cyclosporine A-related nephrotoxicity.